Podcasts about accredited continuing education

  • 16PODCASTS
  • 49EPISODES
  • 49mAVG DURATION
  • 1MONTHLY NEW EPISODE
  • Apr 4, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about accredited continuing education

Latest podcast episodes about accredited continuing education

Rare Disease Discussions
Transforming Clinical Outcomes With Early Treatment of Lysosomal Disorders

Rare Disease Discussions

Play Episode Listen Later Apr 4, 2025 60:10


This CME program provides information on best practices to manage children with lysosomal disorders who have been identified by newborn screening. WIth the wide range of symptoms and severities that present for these rare conditions, it is not always certain when the best time to start treatment is in these patients.Continuing Education InformationThis continuing education activity is provided by AffinityCE and the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC). This activity provides continuing education credit for physicians. A statement of participation is available to other attendees.To obtain credit, visit https://checkrare.com/learning/p-transforming-clinical-outcomes-with-early-treatment-of-lysosomal-disorders/ Faculty and DisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Ozlem Goker-Alpan MDFounder and CMO, Lysosomal & Rare Disorders Research & Treatment CentersDr. Goker-Alpan is on the Advisory Board/Consultant for Chiesi, Takeda, Sanofi, Prevail/Lilly, Sparks Therapeutics, Uniqure, Exegenesis, Astellas, Freeline, Team Sanfilippo. She receives grants/research support from Chiesi, Sanofi, Takeda, Prevail/Lilly, Spark Therapeutics, Amicus, Freeline, Sangamo, Cyclo, Odorsia, DMT, Homology, Protaliz. She is on the speaker bureau for Sanofi, Takeda, Amicus, ChiesiDavid F. Kronn MDAssociate Professor of Pathology and Pediatrics                                                New York Medical CollegeDr. Kronn is on the Advisory Board for Sanofi. He is also on the speaker bureau for Sanofi. He receives research funding from Sanofi.Uma Ramaswami FRCPCH, MDRoyal Free London Hospitals & Genetics and Genomic Medicine, University College LondonDr. Ramaswami is on the Advisory Board for Amicus, Chiesi, Sanofi and Takeda. She receives research grants from Chiesi and Intabio.Liz Jalazo MDAssistant Professor of Pediatrics and GeneticsUniversity of North Carolina at Chapel HillDr. Jalazo is on the Advisory Board for Sanofi and Ionis. Lindsay Torrice MSN, CPNP-PC MDAssistant Professor of PediatricsUniversity of North Carolina at Chapel HillMs. Torrice has no financial relationships to disclose.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. All relevant financial relationships for faculty were mitigated by the peer review of content by non-conflicted reviewers before the commencement of the activity.Learning ObjectivesAt the end of this activity, participants should be able to:•     Cite the importance of early diagnosis and treatment of lysosomal storage disorders•     List the guidelines for the early treatment of LDs and enhanced integration of newborn screening programs•     Identify key research gaps and priorities and strengthen collaboration among researchers and healthcare professionals•     List the educational resources and support programs for familiesPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other healthcare professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.Commercial SupportThis activity was supported by educational grants from Takeda, Sanofi, and Chiesi.Participation CostsThere is no cost to participate in this activity. CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.com.Send customer support requests to cds_support+ldrtc@affinityced.com.

Write Medicine
Follow the Money: The Unexpected Economics of CME

Write Medicine

Play Episode Listen Later Jan 29, 2025 14:48


Is private equity's growing influence in continuing medical education changing the quality of learning in the health professions? As a CME professional, you need to navigate an increasingly complex funding landscape where commercial support has dropped, and private equity firms are rapidly acquiring education providers. Understanding these shifts is crucial for developing sustainable, high-quality educational programs and navigating your way as a CME professional. In this episode, we'll explore: How CME funding has evolved from primarily university-based to a complex mix of commercial support, registration fees, and private investment Why private equity firms are acquiring CME providers and what this means for content development Key strategies for maintaining educational quality and professional relationships in an environment of frequent mergers and acquisitions Listen now to gain insights into the $4.23 billion CME industry's funding transformation and position yourself for success in this rapidly changing landscape. Timestamps 00:00 Introduction: The Art of Hustling Pool and CME 00:54 AI Bootcamp for Medical Writers 01:32 The Complex Financial Side of CME 02:06 Evolution of CME Funding 02:42 Pharmaceutical Influence and Regulations 05:47 The Impact of Compliance and Regulatory Codes 07:06 Current CME Funding Landscape 08:21 Private Equity in CME 10:48 Challenges and Questions for CME Professionals 12:08 Conclusion: Ensuring Educational Quality Resources Ratnasekera A, Impact of private equity on graduate medical education: A slippery slope. Am J Surg. https://doi.org/10.1016/j.amjsurg.2024.116160 ACCME's Standards for Integrity and Independence in Continuing Education (2020) ACCME Data Report. Thriving Through Growth and Innovation—2023. ACCME. Toolkit for the Standards for Integrity and Independence in Accredited Continuing Education

Rare Disease Discussions
Cushing's Syndrome Treatment Research Highlights: ENDO 2024Continuing Education

Rare Disease Discussions

Play Episode Listen Later Sep 30, 2024 33:04


This continuing education activity is provided by AffinityCE and CheckRare CE. This activity provides continuing education credit for physicians. A statement of participation is available for other attendees. Estimated time to complete: 0.50 hoursTo obtain CME credit, go to https://checkrare.com/learning/p-cushings-syndrome-treatment-research-highlights-endo-2024/Commercial SupportEducational Support for this activity was provided by Recordati Rare Diseases, Inc., and Xeris Pharmaceuticals.Learning ObjectiveAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with Cushing's syndrome and its clinical relevance.Share new information with their clinical team. Activity DescriptionThis 30-minute CME program highlights the latest clinical research about Cushing's syndrome and Cushing' disease.Cushing's syndrome is rare endocrine disorder characterized by chronic hypercortisolism. It is often due to a pituitary adenoma producing excessive ACTH leading to hypercortisolism. Symptoms can range from mild to extensive.This CME program, hosted by Maria Fleseriu, MD, FACE, Professor of Medicine and Neurological Surgery, Director of the Pituitary Center at Oregon Health & Science University, provides an overview of the latest clinical research presented at ENDO 20234 involving Cushing's syndrome. FacultyMaria Fleseriu, MD, FACEProfessor of Medicine and Neurological SurgeryDirector of Pituitary CenterOregon Health & Science UniversityPortland, OregonDisclosure StatementAffinityCE and CheckRare CE staff, as well as planning and review committees, have no financial interests to disclose. Faculty EducatorsDr. Fleseriu discloses the following relevant financial relationships with ineligible companies to disclose:Funding to the University as Principle Investigator from Sparrow PharmaceuticalsScientific consultant for Crinetics Pharmaceuticals, Recordati Rare Diseases, Sparrow Pharmaceuticals, and Xeris PharmaceuticalsMitigation of Relevant Financial Relationships AffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre- and post-program assessments. Your certificate will be emailed to you in within 30 days.Participation CostsThere is no cost to participate in this CME session. To receive CME credit for your participation, please complete the pre- and post-program assessments. Your certificate will be emailed to you in within 30 days.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.com.Send customer support requests to cds_support+ldrtc@affinityced.com.Copyright© 2024. This CME-certified activity is held as copyrighted © by AffinityCE and CheckRare CE. Through this notice, AffinityCE and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s). 

Ridgeview Podcast: CME Series
"Postpartum Hemorrhage: The Patient and The Doctor" with Dr. Dennis Mohling and Abie Rosckes

Ridgeview Podcast: CME Series

Play Episode Listen Later May 24, 2024 70:30


In this final podcast of the Ridgeview CME Podcast Series [sigh], Dr. Dennis Mohling, an obstetrician/gynecologist with Western OB/GYN, a Division of Ridgeview Clinics, along with one of his patients, Abie Rosckes discuss a special case around a improbable postpartum event and the decisions that were made. *Disclosure note: None of the speakers or planners for this education activity have relevant financial relationships to disclose with any inelgible company - who's primary business is producing marketing, selling, re-selling, or distributin healthcare products used by or on patients. Enjoy the podcast. Objectives:Upon completion of this podcast, participants should be able to: Explain the presentation of late postpartum hemorrhage (PPH). Distinguish the need for rapid evaluation and treatment of late postpartum hemorrhage (PPH). Summarize the team members and resources needed (and available) to ensure rapid delivery of treatment in a patient experiencing postpartum hemorrhage. This activity has been planned and implemented in accordance with the accreditation criteria, standards and policies of the Minnesota Medical Association (MMA). Ridgeview is accredited by the Minnesota Medical Association (MMA) to provide continuing medical education for physicians.  CME credit is only offered to Ridgeview Providers & Allied Health staff for this podcast activity. After listening to the podcast, complete and submit the online evaluation form. Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at Education@ridgeviewmedical.org. Click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. None of Ridgeview's CME planning committee members have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.  All of the relevant financial relationships for the individuals listed above have been mitigated. Thank-you for listening to the podcast. Thanks to Dr. Dennis Mohling and Abbie Roskes for their expert knowlege and contribution to this podcast. Also a special thanks to Jason Hicks and Fred DeMeuse for their contribution to all the Ridgeview CME Podcasts the past 6 seasons, as they made the educational podcasts fun and entertaining.

Ridgeview Podcast: CME Series
2024 Emergency Medicine Journal Review with Jason Hicks, PA-C, Fred DeMeuse, PA-C, Greta Sowels, PA-C, and Dr. Chris Solie

Ridgeview Podcast: CME Series

Play Episode Listen Later May 6, 2024 78:47


In this podcast, Dr. Chris Solie, an emergency physician, along with Jason Hicks, Fred DeMeuse, Greta Sowels (physician assistants), working for Emergency Medicine Physicians and Consultants (EMPAC) who review journals and papers around emergency medicine. *Disclosure note: None of the speakers or planners for this education activity have relevant financial relationships to disclose with any inelgible company - who's primary business is producing marketing, selling, re-selling, or distributin healthcare products used by or on patients. Enjoy the podcast. Objectives:Upon completion of this podcast, participants should be able to: Identify emergency medicine journal articles that may be potentially practice changing. Differentiate between using a HEAR score versus a HEART score when assessing patients coming into the ED with chest pain. Restate whether vaccination during pregnancy could reduce the burden of respiratory syncytial virus (RSV) - associated lower respiratory tract illness in newborns and infants. Discuss the rate of wound infection from suturing with sterile gloves, dressings, drapes, etc. versus non-sterile gloves, dressings in emergency department. Discuss the risk-benefit of using tranexamic acid (TXA) in the treatment of gastrointestional bleeds. Identify interventions designed to reduce fatigue among emergency department physicians. Determine whether a direct oral penicillin challenge is noninferior to the standard of care of penicillin skin testing followed by an oral challenge in patients with a low-risk pencillin allergy. This activity has been planned and implemented in accordance with the accreditation criteria, standards and policies of the Minnesota Medical Association (MMA). Ridgeview is accredited by the Minnesota Medical Association (MMA) to provide continuing medical education for physicians.  CME credit is only offered to Ridgeview Providers & Allied Health staff for this podcast activity. After listening to the podcast, complete and submit the online evaluation form. Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at Education@ridgeviewmedical.org. Click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. None of Ridgeview's CME planning committee members have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.  All of the relevant financial relationships for the individuals listed above have been mitigated. RESOURCES Article 1: O'Rielly, C.M., Andruchow, J.E., McRae, A.D. et al. External validation of a low HEAR score to identify emergency department chest pain patients at very low risk of major adverse cardiac events without troponin testing. Can J Emerg Med 24, 68–74 (2022). https://doi.org/10.1007/s43678-021-00159-y Article 2: Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023;388(16):1451-1464. doi:10.1056/NEJMoa2216480 Article 3: Zwaans JJM, Raven W, Rosendaal AV, et al. Non-sterile gloves and dressing versus sterile gloves, dressings and drapes for suturing of traumatic wounds in the emergency department: a non-inferiority multicentre randomised controlled trial. Emerg Med J. 2022;39(9):650-654. doi:10.1136/emermed-2021-211540 Article 4: HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet. 2020;395(10241):1927-1936. doi:10.1016/S0140-6736(20)30848-5 Article 5: Fowler LA, Hirsh EL, Klinefelter Z, Sulzbach M, Britt TW. Objective assessment of sleep and fatigue risk in emergency medicine physicians. Acad Emerg Med. 2023;30(3):166-171. doi:10.1111/acem.14606 Article 6: Copaescu AM, Vogrin S, James F, et al. Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial. JAMA Intern Med. 2023;183(9):944-952. doi:10.1001/jamainternmed.2023.2986   Thank-you for listening to the podcast. Thanks to Dr. Chris Solie, Jason Hicks, Fred DeMeuse and Greta Sowels for their expert knowledge and contribution to this podcast.

Ridgeview Podcast: CME Series
Immunotherapy in Cancer with Dr. Purvi Gada and Alicia Wojchik, CNP

Ridgeview Podcast: CME Series

Play Episode Listen Later Apr 15, 2024 44:34


In this podcast, Dr. Purvi Gada, a hematologist and oncologist, along with Alicia Wojchik, a nurse practitioner, both with Minnesota Oncology, come together to discuss immunotherapy in regards to cancer treatment. Enjoy the podcast. Objectives:Upon completion of this podcast, participants should be able to: Describe how the immune system functions (works), and how it impacts immunotherapy. Define the difference between immunotherapy and chemotherapy. Describe how immunotherapy drugs work. Identify and manage side effects of immunotherapy. This activity has been planned and implemented in accordance with the accreditation criteria, standards and policies of the Minnesota Medical Association (MMA). Ridgeview is accredited by the Minnesota Medical Association (MMA) to provide continuing medical education for physicians.  CME credit is only offered to Ridgeview Providers & Allied Health staff for this podcast activity. After listening to the podcast, complete and submit the online evaluation form. Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at Education@ridgeviewmedical.org. Click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. None of Ridgeview's CME planning committee members have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.  All of the relevant financial relationships for the individuals listed above have been mitigated. Thank-you for listening to the podcast. Thanks to Dr. Purvi Gada and Alicia Wojchik for their expert knowledge and contribution to this podcast.

Ridgeview Podcast: CME Series
Evidence Based Medicine and Deciphering the Literature with Dr. Brian Driver

Ridgeview Podcast: CME Series

Play Episode Listen Later Mar 25, 2024 54:39


In this podcast, Dr. Brian Driver, an emergency medicine physician with Hennepin Healthcare, brings his research expertise to this podcast and will help to decipher the complexities of research articles, what makes a good study, and how we can better interpret the literature. Enjoy the podcast. Objectives:Upon completion of this podcast, participants should be able to: Define what is meant by "evidence-based medicine". Explain what makes a good research study. Correctly interpret findings in research articles. This activity has been planned and implemented in accordance with the accreditation criteria, standards and policies of the Minnesota Medical Association (MMA). Ridgeview is accredited by the Minnesota Medical Association (MMA) to provide continuing medical education for physicians.  CME credit is only offered to Ridgeview Providers & Allied Health staff for this podcast activity. After listening to the podcast, complete and submit the online evaluation form. Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at Education@ridgeviewmedical.org. Click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. None of Ridgeview's CME planning committee members have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.  All of the relevant financial relationships for the individuals listed above have been mitigated. Thank-you for listening to the podcast. Thanks to Dr. Brian Driver for his expert knowledge and contribution to this podcast.

Rounding@IOWA
66: Evidenced-Based Orthopedic Regenerative Medicine

Rounding@IOWA

Play Episode Listen Later Mar 12, 2024 34:15


What is regenerative medicine?  How can it help patients?  What options are available?  Join us today as we discuss these topics. CME Credit Available:  https://uiowa.cloud-cme.com/course/courseoverview?P=0&EID=48288   Host: Gerard Clancy, MD Senior Associate Dean for External Affairs Professor of Psychiatry and Emergency Medicine University of Iowa Carver College of Medicine Guest: Ryan Kruse, MD Clinical Assistant Professor of Orthopedics and Rehabilitation University of Iowa Health Care Disclosure Policy: University of Iowa Roy J. and Lucille A. Carver College of Medicine adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships have been mitigated prior to the commencement of the activity. CME Credit Designation: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other Health Care Providers: A certificate of completion will be available after successful completion of the course. (It is the responsibility of licensees to determine if this continuing education activity meets the requirements of their professional licensure board.)  

Rare Disease Discussions
Kidney Involvement in Lysosomal Disorders

Rare Disease Discussions

Play Episode Listen Later Mar 5, 2024 60:00


Ozlem Goker-Alpan, MD, Founder and President, LDRTC and David G. Warnock, MD. Professor of Medicine (Emeritus) at University of Alabama at Birmingham discuss best practices to identify and treat kidney problems associated with lysosomal disorders.This CME/CE activity describes the pathophysiologies and management options for lysosomal disease patients with kidney problems. This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees. To receive credit for this program, go to https://checkrare.com/learning/ Speakers Ozlem Goker-Alpan, MD, Founder and President, LDRTC David G. Warnock, MD. Professor of Medicine (Emeritus)University of Alabama at BirminghamDisclosuresAffinityCE staff, LDRTC staff, CheckRare staff, planners, and reviewers, have no relevant financial interests to disclose. All faculty disclosures are listed below and are included in the beginning of each presentation.Dr. Goker-Alpan is a consultant, a principal investigator and /or on the speaker bureau, or has received grant support, from the following pharmaceutical companies: Actelion, Amicus Therapeutics, Sanofi, Takeda, Pfizer/Protalix.Dr. Warnock has had research support and/or consulting arrangements with Genzyme Corporation (Sanofi), Shire LLC (Takeda), Amicus, Protalix and Chiesi, Zebra Bio, Walking Fish, Hanmi, and Vera Therapeutics.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Learning ObjectivesAt the end of this activity, participants should be able to:Describe the role of the nephrologist in the team approach to careDescribe best practices to monitor kidney function in lysosomal disordersDescribe best practices to treat kidney disorders lysosomal disordersSupport for this educational activity was provided by Takeda, Sanofi, Amicus Therapeutics and Chiesi USA.

Ridgeview Podcast: CME Series
Models of Care and Reimbursements in Geriatrics with Dr. Nick Schneeman

Ridgeview Podcast: CME Series

Play Episode Listen Later Mar 4, 2024 72:29


In this podcast, Dr. Nick Schneeman, a geriatrican and the Chief Medical Officer for LifeSpark, brings his passion and expertise to discuss the state of care in geriatrics, along with how current delivery in care and payment models effect the geriatric population. Disclosure note: Dr. Nick Schneeman , speaker for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose. Enjoy the podcast. Objectives:Upon completion of this podcast, participants should be able to: Describe what is meant by "value-based care". Describe current barriers to delivering high value care to a senior population. This activity has been planned and implemented in accordance with the accreditation criteria, standards and policies of the Minnesota Medical Association (MMA). Ridgeview is accredited by the Minnesota Medical Association (MMA) to provide continuing medical education for physicians.  CME credit is only offered to Ridgeview Providers & Allied Health staff for this podcast activity. After listening to the podcast, complete and submit the online evaluation form. Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at Education@ridgeviewmedical.org. Click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. None of Ridgeview's CME planning committee members have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.  All of the relevant financial relationships for the individuals listed above have been mitigated. Thank-you for listening to the podcast. SHOW NOTES:   *See the attachment for additional information.  PODCAST OVERVIEW- Geriatric care delivery and quality has not evolved significiantly. - Pockets of excellence exist in academic centers. - Social support systems is integral, but lacking in many parts of the country. - Fee for service (FFS) system is not a sustainable model per Dr. Schneeman for complex senior patients. - Training and exposure to the 'business platforms' in medicine is lacking with providers - FFS = paying for a specific service, procedure, treatment, etc. Value Based Care (VBC)- Value based care = outcomes/cost         - Clinical outcomes         - Experience outcomes of patient/family and caregiving team - How is VBC measured?         - Medical loss ratio (cost containment) - How does VBC work?         - Organization contracts with payor         - VBC organization takes on risk         - Money savings opportunity - Half of seniors in USA are already in a VBC model         - Medicare (CMS)         - ACO (group of doctors, health care organization, etc.)         - Medicare advantage (CMS product that insurance companies contract with federal government) - Cost Product (Medicare advantage product)         - Introduced in MN with assumption that this state will do such a good job with cost containment, but this wasn't how it worked out.         - For-profits don't participate in Medicare advantage products which keep the non-profits more accountable, although there are also disadvantages with for-profit programs. - How does the care delivery work in VBC organizations (Nick's viewpoint)?         - Step 1: Journey from simple problems into complexity         - Step 2: What is the current reality and quality of life?  (When people hear you restating their story, trust goes up immensily.)         - Step 3: What are you hoping for? (patient, family, etc.)         - Step 4: Acute care planning         - Step 5: Chronic care planning         - Outcomes:  POLST (physician orders for life-sustaining treatment) form that is comprehensive;            Chronic care plans that are clear and purposeful and match goals of care - Well done POLST forms require intential discussion with patient and advocates who have decision making capacity and understanding of the patient's reality and values Palliative Care- How it's integrated and its controversy - All practitioners should be able to make palliative decisions with and for their patients who they know intimately - Palliative care as a specialty exists largely due to a FFS model - Often this is a clinican the patient has never met before and is a one time consult - Private equity had created palliative care 'cold call' business models in recent years Value Based Care (VBC) - continued- How does a practitioner go about doing this? - Make sure the organization you join actually values the primacy of primary care - Clinicians need TIME with their complex patients and to be paid for this time - FFS can work well for simple problems - Who does this well? Small pockets, mostly senior care (i.e. clinic-based, homebased healthcare etc.) - Nurse, APP, physician - are assigned to each patient and continue to follow their care, avoid overprescribing, inappropriate abx - Private equity and Big insurance is getting into the game, but their approaches tend to be siloed and perhaps less humanistic - Recruiting quality providers to this care delivery model is imperative - Improved patient outcomes and costs exisst (i.e. geriatric assessment before cancer care) - Value Based Care really has to be an "all in" experience for a clinic or organization for it to work Training- Training typically happens in house, as opposed to a training program or course - Subspecialists will still be very much part of the care team, although decision making about proceeding with advanced therapies will be oriented around the VBC  medical home team - Pharmacy is a valuable team member as well, especially if part of the "goals of care" as opposed to merely looking up medications - Challenge: SNFs and long term care facilities often have significant staff turnover, care quality issues, and these can lead to unnecessary care, ED visits and hospitalizations Evidence Based Moment (EBM)  ResourcesMagill MK. Time to Do the Right Thing: End Fee-for-Service for Primary Care. Ann Fam Med. 2016 Sep;14(5):400-1. doi: 10.1370/afm.1977. PMID: 27621155; PMCID: PMC5394371. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394371/pdf/0140400.pdf Basu S, Phillips RS, Song Z, Landon BE, Bitton A. Effects of New Funding Models for Patient-Centered Medical Homes on Primary Care Practice Finances and Services: Results of a Microsimulation Model. Ann Fam Med. 2016 Sep;14(5):404-14. doi: 10.1370/afm.1960. PMID: 27621156; PMCID: PMC5394379. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.annfammed.org/content/annalsfm/14/5/404.full.pdf Thanks to Dr. Nick Schneeman for his expert knowledge and contribution to this podcast.

Rare Disease Discussions
Assessing, Monitoring, and Managing Respiratory Involvement in Lysosomal Disorders

Rare Disease Discussions

Play Episode Listen Later Mar 3, 2024 51:44


Ozlem Goker-Alpan, MD of LDRTC and John Bach, MD, Professor of Neurology at Rutgers School of Medicine discuss best practices to manage respiratory complications in persons with lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees. To receive credit for this program, visit https://checkrare.com/learning/p-ldrtc2023-webinar3-assessing-monitoring-managing-respiratory-involvement-in-lysosomal-disorders/DisclosuresAffinityCE staff, LDRTC staff, CheckRare staff, planners, and reviewers, have no relevant financial interests to disclose. All faculty disclosures are listed below and are included in the beginning of each presentation.Ozlem Goker-Alpan, MDFounder and President, Lysosomal & Rare Disorders Research & Treatment Center (LDRTC).Dr. Goker-Alpan is a consultant, a principal investigator and /or on the speaker bureau, or has received grant support, from the following pharmaceutical companies: Actelion, Amicus Therapeutics, Sanofi, Takeda, Pfizer/Protalix.John Bach, MDProfessor of Physical Medicine and Rehabilitation, Professor of Neurology, Rutgers New Jersey Medical Center.Dr. Bach has no relevant financial interest to disclose.Mitigation of Relevant Financial Relationships AffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Learning ObjectivesAt the end of this activity, participants should be able to:• Describe the most common LSDs that have pulmonary complications. • Describe best practices to manage pulmonary symptoms in Pompe disease. • Describe best practices to manage pulmonary symptoms in MPSs.• Describe best practices to manage sleep apnea in lysosomal diseases.PhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesContinuing Nursing Education is provided for this program through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1.25 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic Counselors Category 2 CEUAffinityCE designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Genetic counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.Commercial Support Support for this educational activity was provided by Takeda, Sanofi, Amicus Therapeutics and Chiesi USA. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.com.Send customer support requests to cds_support+ldrtc@affinityced.com.

Ridgeview Podcast: CME Series
Vascular Insufficiency - Between Diagnosis, Management and Outcome with Dr. Nedaa Skeik

Ridgeview Podcast: CME Series

Play Episode Listen Later Feb 12, 2024 54:43


In this podcast, Dr. Nedaa Skeik, a vascular surgeon with Minneapolis Heart Institute, brings his knowledge and experience in regards to vascular insufficiency, and the importance of a timely diagnosis and management options. *Disclosure note: Dr. Nedaa Skeik, speaker for this educational event, has disclosed that he received honorarium from Medtronic.  All relevant financial relationships for Dr. Skeik have been mitigated. Enjoy the podcast. Objectives:Upon completion of this podcast, participants should be able to: Summarize the pathophysiology of different venous disorders. Recognize and confidently diagnose venous insufficiency. Identify the risks and benefits of different interventions for venous conditions. Differentiate medical management (conservative and interventional) for venous insufficiency. This activity has been planned and implemented in accordance with the accreditation criteria, standards and policies of the Minnesota Medical Association (MMA). Ridgeview is accredited by the Minnesota Medical Association (MMA) to provide continuing medical education for physicians.  CME credit is only offered to Ridgeview Providers & Allied Health staff for this podcast activity. After listening to the podcast, complete and submit the online evaluation form. Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at Education@ridgeviewmedical.org. Click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. None of Ridgeview's CME planning committee members have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.  All of the relevant financial relationships for the individuals listed above have been mitigated. Thank-you for listening to the podcast. SHOW NOTES:   *See the attachment for additional information.  PODCAST OVERVIEW Wide Range of Venous Disorders and Presentations - Morphologic (spider, reticular, varicose), skin discoloration, ulceration - Functional (venous reflux +/- loss of pumping mechanism - Anatomic (thrombosis, congenital anomalies) - Presentation (asymptomatic vs symptomatic)Anatomy PathophysiologyEpidemiology - Chronic vein abnormalities- Prevalence (venous insufficiency) - Varicose veins & prevalence- Presence of symptoms Risk factors - Family component- Other  Clinical features - Correlation - severity of venous reflux, age- Asymptomatic - General symptoms - Vein appearance - Severity Disease Severity - Classification Scales - CEAP calssification scale- Venous Clinial Severity Score  Disease Progression - Correlation- pregression of disease not well understoodDiagnosis - History - Symptoms - Exam findings - including venous ultrasound - Differential diagnoses (edema, skin manifestations, vein engorgement) - Pre-management considerations (severity, superficial and/or deep, proximal/distal, multiple or single, comorbidities) ManagementAsymptomatic - visual sclerotherapy- surface laser therapy - complications Symptomatic- compression therapy - exercise - leg elevation - skin care Conserative Therapy- leg elevation - exercise - compression stockings Pharmacologic Therapy and Skin Care- vasoactive drugs - rheologic agents - skin care Interventional Options - Preintervention measures (venous anatomy, preop medications, anesthesia) - Sclerotherapy (visual, US guided)- Vein closure procedures (thermal - RFA/EVLA, chemical, MOCA, PEM, EHIT) - Surgical (phlebectomy, ligation, stripping) Post Intervention Care - pain management - ambulation - leg elevation - compression - return to normal activity/work - post procedural US - follow up appointment Thanks to Dr. Nedaa Skeik for his expert knowledge and contribution to this podcast. Please check out the additional show notes for more information/resources.

Ridgeview Podcast: CME Series
Aortic Valve Disease: What Clinicians Should Know with Dr. Robert Steffen

Ridgeview Podcast: CME Series

Play Episode Listen Later Dec 12, 2023 50:51


In this podcast, Dr. Robert Steffen, a cardiac surgeon with Minneapolis Heart Institute. Dr. Steffen brings his knowledge and experience regarding the prevalence of aortic valve disease, advancements in technology, as well as treatment modalities for patients who suffer with this problematic disorder. Enjoy the podcast. Objectives:Upon completion of this podcast, participants should be able to: State the prevalence of aortic valve disease. Identify when patients with aortic valve disease need intervention. Describe the different therapeutic options for patients with aortic valve disease and when to use them. This activity has been planned and implemented in accordance with the accreditation criteria, standards and policies of the Minnesota Medical Association (MMA). Ridgeview is accredited by the Minnesota Medical Association (MMA) to provide continuing medical education for physicians.  CME credit is only offered to Ridgeview Providers & Allied Health staff for this podcast activity. After listening to the podcast, complete and submit the online evaluation form. Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at Education@ridgeviewmedical.org. Click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. Ridgeview's CME planning committee members and presenter(s) have disclosed they have no significant financial relationship with a pharmaceutical company and have disclosed that no conflict of interest exists with the presentation/educational event. Thank-you for listening to the podcast.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Amy S. Paller, MD - Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted Treatment

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Nov 24, 2023 51:59


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZTQ865. CME/MOC/AAPA credit will be available until November 8, 2024.Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted TreatmentAtopic dermatitis (AD) is a chronic disease that affects a large proportion of the US population and is associated with a heavy disease burden that affects patients and their families. Topical treatment options for AD have limitations related to efficacy, tolerability, and safety concerns but the availability of biologic agents for both pediatric and adult patients with AD has revitalized the treatment landscape for this chronic disease. However, challenges remain with the identification and assessment of severity of AD, particularly with regard to age- and race-related differences in AD features, and with utilizing targeted therapy appropriately, especially in pediatric patients. This activity will provide learners with expert guidance regarding the identification and assessment of AD severity in children and practical strategies regarding the integration of targeted biologic therapy for pediatric patients with moderate to severe AD.ChairAmy S. Paller, MDNorthwestern University Feinberg School of MedicineChicago, IllinoisPatient AdvocateKacey Jenkins In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Eczema Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy S. Paller, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Abeona Therapeutics Inc.; Aegerion Pharmaceuticals Inc.; Azitra; BioCryst Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Castle Creek Biosciences, Inc.; Catawba Research, LLC; Galderma S.A.; InMed Pharmaceuticals, Inc.; Johnson and Johnson Services, Inc.; Krystal Biotech, Inc.; Leo Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; SanofiGenzyme; TWi Biotechnology, Inc.; and UCB, Inc.Grant/Research Support from Castle Creek Biosciences, Inc.; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Krystal Biotech, Inc; Lilly; Regeneron Pharmaceuticals Inc.; and UCB, Inc.Patient Advocate/PlannerKacey Jenkins has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 24, 2023 63:53


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Amy S. Paller, MD - Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted Treatment

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 24, 2023 51:37


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZTQ865. CME/MOC/AAPA credit will be available until November 8, 2024.Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted TreatmentAtopic dermatitis (AD) is a chronic disease that affects a large proportion of the US population and is associated with a heavy disease burden that affects patients and their families. Topical treatment options for AD have limitations related to efficacy, tolerability, and safety concerns but the availability of biologic agents for both pediatric and adult patients with AD has revitalized the treatment landscape for this chronic disease. However, challenges remain with the identification and assessment of severity of AD, particularly with regard to age- and race-related differences in AD features, and with utilizing targeted therapy appropriately, especially in pediatric patients. This activity will provide learners with expert guidance regarding the identification and assessment of AD severity in children and practical strategies regarding the integration of targeted biologic therapy for pediatric patients with moderate to severe AD.ChairAmy S. Paller, MDNorthwestern University Feinberg School of MedicineChicago, IllinoisPatient AdvocateKacey Jenkins In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Eczema Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy S. Paller, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Abeona Therapeutics Inc.; Aegerion Pharmaceuticals Inc.; Azitra; BioCryst Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Castle Creek Biosciences, Inc.; Catawba Research, LLC; Galderma S.A.; InMed Pharmaceuticals, Inc.; Johnson and Johnson Services, Inc.; Krystal Biotech, Inc.; Leo Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; SanofiGenzyme; TWi Biotechnology, Inc.; and UCB, Inc.Grant/Research Support from Castle Creek Biosciences, Inc.; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Krystal Biotech, Inc; Lilly; Regeneron Pharmaceuticals Inc.; and UCB, Inc.Patient Advocate/PlannerKacey Jenkins has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Nov 24, 2023 63:56


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Nov 24, 2023 63:56


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 24, 2023 63:53


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 24, 2023 63:53


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Amy S. Paller, MD - Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted Treatment

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 24, 2023 51:37


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZTQ865. CME/MOC/AAPA credit will be available until November 8, 2024.Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted TreatmentAtopic dermatitis (AD) is a chronic disease that affects a large proportion of the US population and is associated with a heavy disease burden that affects patients and their families. Topical treatment options for AD have limitations related to efficacy, tolerability, and safety concerns but the availability of biologic agents for both pediatric and adult patients with AD has revitalized the treatment landscape for this chronic disease. However, challenges remain with the identification and assessment of severity of AD, particularly with regard to age- and race-related differences in AD features, and with utilizing targeted therapy appropriately, especially in pediatric patients. This activity will provide learners with expert guidance regarding the identification and assessment of AD severity in children and practical strategies regarding the integration of targeted biologic therapy for pediatric patients with moderate to severe AD.ChairAmy S. Paller, MDNorthwestern University Feinberg School of MedicineChicago, IllinoisPatient AdvocateKacey Jenkins In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Eczema Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy S. Paller, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Abeona Therapeutics Inc.; Aegerion Pharmaceuticals Inc.; Azitra; BioCryst Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Castle Creek Biosciences, Inc.; Catawba Research, LLC; Galderma S.A.; InMed Pharmaceuticals, Inc.; Johnson and Johnson Services, Inc.; Krystal Biotech, Inc.; Leo Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; SanofiGenzyme; TWi Biotechnology, Inc.; and UCB, Inc.Grant/Research Support from Castle Creek Biosciences, Inc.; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Krystal Biotech, Inc; Lilly; Regeneron Pharmaceuticals Inc.; and UCB, Inc.Patient Advocate/PlannerKacey Jenkins has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Nov 24, 2023 63:56


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Amy S. Paller, MD - Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted Treatment

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Nov 24, 2023 51:59


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZTQ865. CME/MOC/AAPA credit will be available until November 8, 2024.Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted TreatmentAtopic dermatitis (AD) is a chronic disease that affects a large proportion of the US population and is associated with a heavy disease burden that affects patients and their families. Topical treatment options for AD have limitations related to efficacy, tolerability, and safety concerns but the availability of biologic agents for both pediatric and adult patients with AD has revitalized the treatment landscape for this chronic disease. However, challenges remain with the identification and assessment of severity of AD, particularly with regard to age- and race-related differences in AD features, and with utilizing targeted therapy appropriately, especially in pediatric patients. This activity will provide learners with expert guidance regarding the identification and assessment of AD severity in children and practical strategies regarding the integration of targeted biologic therapy for pediatric patients with moderate to severe AD.ChairAmy S. Paller, MDNorthwestern University Feinberg School of MedicineChicago, IllinoisPatient AdvocateKacey Jenkins In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Eczema Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy S. Paller, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Abeona Therapeutics Inc.; Aegerion Pharmaceuticals Inc.; Azitra; BioCryst Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Castle Creek Biosciences, Inc.; Catawba Research, LLC; Galderma S.A.; InMed Pharmaceuticals, Inc.; Johnson and Johnson Services, Inc.; Krystal Biotech, Inc.; Leo Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; SanofiGenzyme; TWi Biotechnology, Inc.; and UCB, Inc.Grant/Research Support from Castle Creek Biosciences, Inc.; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Krystal Biotech, Inc; Lilly; Regeneron Pharmaceuticals Inc.; and UCB, Inc.Patient Advocate/PlannerKacey Jenkins has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Ridgeview Podcast: CME Series
Fulfillment and Resilience in Medicine and Life with Dr. Michael Maddaus

Ridgeview Podcast: CME Series

Play Episode Listen Later Nov 10, 2023 71:41


In this podcast, Dr. Michael Maddaus, a retired thoracic surgeon, but currently a physician coach with a special interest in helping surgeons.  Dr. Maddaus brings his knowledge and experience around burnout, wellness, resiliency and other healthcare provider challenges. Enjoy the podcast. Objectives:Upon completion of this podcast, participants should be able to: Define reslience and identify how it applies to adversities encountered in medicine. Identify behaviors that promote resilience, including managing expectations, setting realistic goals and finding gratitude. This activity has been planned and implemented in accordance with the accreditation criteria, standards and policies of the Minnesota Medical Association (MMA). Ridgeview is accredited by the Minnesota Medical Association (MMA) to provide continuing medical education for physicians.  CME credit is only offered to Ridgeview Providers & Allied Health staff for this podcast activity. After listening to the podcast, complete and submit the online evaluation form. Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at Education@ridgeviewmedical.org. Click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. Ridgeview's CME planning committee members and presenter(s) have disclosed they have no significant financial relationship with a pharmaceutical company and have disclosed that no conflict of interest exists with the presentation/educational event. Thank-you for listening to the podcast. SHOW NOTES:   *See the attachment for additional information.  PODCAST NOTES & REFERENCES Resilience Bank Account scientific paper: https://www.annalsthoracicsurgery.org/article/S0003-4975(19)31352-9/fulltext Podcast by Dr. Maddaus: https://www.sts.org/topics/resilient-surgeon Authors and Sites Referenced Love + Work by Marcus Buckingham www.principlesyou.com  (Ray Dalio) www.jocko.com  (Jocko Willink) Dark Horse by Todd Rose The End of Average by Todd Rose Waking Up and www.wakingup.com by Sam Harris www.michaelmaddaus.com Thanks goes out to Dr. Michael Maddaus for his expert knowledge and contribution to this podcast. Please check out the additional show notes for more information/resources.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP / Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE - Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Consideratio

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Nov 7, 2023 57:40


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/EUC865. NCPD/CE/AAPA credit will be available until November 11, 2024.Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered CareOptimal management of depression begins with adequate screening and early introduction of appropriate therapy. However, monoaminergic antidepressant therapies, which are currently considered the standard of care, have several limitations, such as slow therapeutic response times, suboptimal efficacy and remission rates, and adverse effects that may impact patient adherence.Recent research has focused on novel pathways involved in the etiology of depression, including glutamatergic and GABAergic modulation. For example, neuroactive steroids such as zuranolone act as positive allosteric modulators of the GABA-A receptor. In 2023, zuranolone became the first and only oral therapy to be approved for the treatment of postpartum depression. There have also been advances in glutamatergic antidepressants, with the approval of esketamine nasal spray for treatment-resistant depression in 2019 and for depression with acute suicidal ideation or behavior in 2020, as well as the approval of dextromethorphan-bupropion for the treatment of major depressive disorder in 2022.In order to help clinicians remain abreast of the latest treatment options for depression, PeerView recently held a Candid Conversations & Clinical Consults educational symposium, featuring a panel of psychiatric–mental health nursing faculty. These depression experts paired compelling, real-world case scenarios with practice-changing evidence to illustrate how to integrate novel and emerging treatments for depression into clinical practice, including strategies to identify patients who may benefit from these treatments, and how to use shared decision-making to craft individualized treatment plans. If you couldn't watch the live event, this on-demand version is available now!Co-Chair & ModeratorJosh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANPThe Hamilton Group Behavioral Health LLCLas Vegas, NevadaCo-Chair & PresenterRhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUERasmussen UniversityBloomington, Minnesota In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sage Therapeutics and Biogen.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alkermes and Point of Care Network, LLC (POCN).Speaker for Myriad Neuroscience and Point of Care Network, LLC (POCN).Co-Chair/PlannerRhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Point of Care Network (POCN).Speaker for Lippincott Clinical Pulse and Practical Updates in Primary Care.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP / Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE - Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Consideratio

PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast

Play Episode Listen Later Nov 7, 2023 57:40


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/EUC865. NCPD/CE/AAPA credit will be available until November 11, 2024.Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered CareOptimal management of depression begins with adequate screening and early introduction of appropriate therapy. However, monoaminergic antidepressant therapies, which are currently considered the standard of care, have several limitations, such as slow therapeutic response times, suboptimal efficacy and remission rates, and adverse effects that may impact patient adherence.Recent research has focused on novel pathways involved in the etiology of depression, including glutamatergic and GABAergic modulation. For example, neuroactive steroids such as zuranolone act as positive allosteric modulators of the GABA-A receptor. In 2023, zuranolone became the first and only oral therapy to be approved for the treatment of postpartum depression. There have also been advances in glutamatergic antidepressants, with the approval of esketamine nasal spray for treatment-resistant depression in 2019 and for depression with acute suicidal ideation or behavior in 2020, as well as the approval of dextromethorphan-bupropion for the treatment of major depressive disorder in 2022.In order to help clinicians remain abreast of the latest treatment options for depression, PeerView recently held a Candid Conversations & Clinical Consults educational symposium, featuring a panel of psychiatric–mental health nursing faculty. These depression experts paired compelling, real-world case scenarios with practice-changing evidence to illustrate how to integrate novel and emerging treatments for depression into clinical practice, including strategies to identify patients who may benefit from these treatments, and how to use shared decision-making to craft individualized treatment plans. If you couldn't watch the live event, this on-demand version is available now!Co-Chair & ModeratorJosh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANPThe Hamilton Group Behavioral Health LLCLas Vegas, NevadaCo-Chair & PresenterRhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUERasmussen UniversityBloomington, Minnesota In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sage Therapeutics and Biogen.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alkermes and Point of Care Network, LLC (POCN).Speaker for Myriad Neuroscience and Point of Care Network, LLC (POCN).Co-Chair/PlannerRhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Point of Care Network (POCN).Speaker for Lippincott Clinical Pulse and Practical Updates in Primary Care.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP / Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE - Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Consideratio

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Nov 7, 2023 57:40


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/EUC865. NCPD/CE/AAPA credit will be available until November 11, 2024.Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered CareOptimal management of depression begins with adequate screening and early introduction of appropriate therapy. However, monoaminergic antidepressant therapies, which are currently considered the standard of care, have several limitations, such as slow therapeutic response times, suboptimal efficacy and remission rates, and adverse effects that may impact patient adherence.Recent research has focused on novel pathways involved in the etiology of depression, including glutamatergic and GABAergic modulation. For example, neuroactive steroids such as zuranolone act as positive allosteric modulators of the GABA-A receptor. In 2023, zuranolone became the first and only oral therapy to be approved for the treatment of postpartum depression. There have also been advances in glutamatergic antidepressants, with the approval of esketamine nasal spray for treatment-resistant depression in 2019 and for depression with acute suicidal ideation or behavior in 2020, as well as the approval of dextromethorphan-bupropion for the treatment of major depressive disorder in 2022.In order to help clinicians remain abreast of the latest treatment options for depression, PeerView recently held a Candid Conversations & Clinical Consults educational symposium, featuring a panel of psychiatric–mental health nursing faculty. These depression experts paired compelling, real-world case scenarios with practice-changing evidence to illustrate how to integrate novel and emerging treatments for depression into clinical practice, including strategies to identify patients who may benefit from these treatments, and how to use shared decision-making to craft individualized treatment plans. If you couldn't watch the live event, this on-demand version is available now!Co-Chair & ModeratorJosh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANPThe Hamilton Group Behavioral Health LLCLas Vegas, NevadaCo-Chair & PresenterRhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUERasmussen UniversityBloomington, Minnesota In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sage Therapeutics and Biogen.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alkermes and Point of Care Network, LLC (POCN).Speaker for Myriad Neuroscience and Point of Care Network, LLC (POCN).Co-Chair/PlannerRhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Point of Care Network (POCN).Speaker for Lippincott Clinical Pulse and Practical Updates in Primary Care.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP / Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE - Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Consideratio

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 31, 2023 57:37


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/EUC865. NCPD/CE/AAPA credit will be available until November 11, 2024.Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered CareOptimal management of depression begins with adequate screening and early introduction of appropriate therapy. However, monoaminergic antidepressant therapies, which are currently considered the standard of care, have several limitations, such as slow therapeutic response times, suboptimal efficacy and remission rates, and adverse effects that may impact patient adherence.Recent research has focused on novel pathways involved in the etiology of depression, including glutamatergic and GABAergic modulation. For example, neuroactive steroids such as zuranolone act as positive allosteric modulators of the GABA-A receptor. In 2023, zuranolone became the first and only oral therapy to be approved for the treatment of postpartum depression. There have also been advances in glutamatergic antidepressants, with the approval of esketamine nasal spray for treatment-resistant depression in 2019 and for depression with acute suicidal ideation or behavior in 2020, as well as the approval of dextromethorphan-bupropion for the treatment of major depressive disorder in 2022.In order to help clinicians remain abreast of the latest treatment options for depression, PeerView recently held a Candid Conversations & Clinical Consults educational symposium, featuring a panel of psychiatric–mental health nursing faculty. These depression experts paired compelling, real-world case scenarios with practice-changing evidence to illustrate how to integrate novel and emerging treatments for depression into clinical practice, including strategies to identify patients who may benefit from these treatments, and how to use shared decision-making to craft individualized treatment plans. If you couldn't watch the live event, this on-demand version is available now!Co-Chair & ModeratorJosh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANPThe Hamilton Group Behavioral Health LLCLas Vegas, NevadaCo-Chair & PresenterRhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUERasmussen UniversityBloomington, Minnesota In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sage Therapeutics and Biogen.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alkermes and Point of Care Network, LLC (POCN).Speaker for Myriad Neuroscience and Point of Care Network, LLC (POCN).Co-Chair/PlannerRhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Point of Care Network (POCN).Speaker for Lippincott Clinical Pulse and Practical Updates in Primary Care.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP / Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE - Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Consideratio

PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 31, 2023 57:37


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/EUC865. NCPD/CE/AAPA credit will be available until November 11, 2024.Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered CareOptimal management of depression begins with adequate screening and early introduction of appropriate therapy. However, monoaminergic antidepressant therapies, which are currently considered the standard of care, have several limitations, such as slow therapeutic response times, suboptimal efficacy and remission rates, and adverse effects that may impact patient adherence.Recent research has focused on novel pathways involved in the etiology of depression, including glutamatergic and GABAergic modulation. For example, neuroactive steroids such as zuranolone act as positive allosteric modulators of the GABA-A receptor. In 2023, zuranolone became the first and only oral therapy to be approved for the treatment of postpartum depression. There have also been advances in glutamatergic antidepressants, with the approval of esketamine nasal spray for treatment-resistant depression in 2019 and for depression with acute suicidal ideation or behavior in 2020, as well as the approval of dextromethorphan-bupropion for the treatment of major depressive disorder in 2022.In order to help clinicians remain abreast of the latest treatment options for depression, PeerView recently held a Candid Conversations & Clinical Consults educational symposium, featuring a panel of psychiatric–mental health nursing faculty. These depression experts paired compelling, real-world case scenarios with practice-changing evidence to illustrate how to integrate novel and emerging treatments for depression into clinical practice, including strategies to identify patients who may benefit from these treatments, and how to use shared decision-making to craft individualized treatment plans. If you couldn't watch the live event, this on-demand version is available now!Co-Chair & ModeratorJosh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANPThe Hamilton Group Behavioral Health LLCLas Vegas, NevadaCo-Chair & PresenterRhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUERasmussen UniversityBloomington, Minnesota In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sage Therapeutics and Biogen.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alkermes and Point of Care Network, LLC (POCN).Speaker for Myriad Neuroscience and Point of Care Network, LLC (POCN).Co-Chair/PlannerRhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Point of Care Network (POCN).Speaker for Lippincott Clinical Pulse and Practical Updates in Primary Care.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP / Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE - Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Consideratio

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 31, 2023 57:37


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/EUC865. NCPD/CE/AAPA credit will be available until November 11, 2024.Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered CareOptimal management of depression begins with adequate screening and early introduction of appropriate therapy. However, monoaminergic antidepressant therapies, which are currently considered the standard of care, have several limitations, such as slow therapeutic response times, suboptimal efficacy and remission rates, and adverse effects that may impact patient adherence.Recent research has focused on novel pathways involved in the etiology of depression, including glutamatergic and GABAergic modulation. For example, neuroactive steroids such as zuranolone act as positive allosteric modulators of the GABA-A receptor. In 2023, zuranolone became the first and only oral therapy to be approved for the treatment of postpartum depression. There have also been advances in glutamatergic antidepressants, with the approval of esketamine nasal spray for treatment-resistant depression in 2019 and for depression with acute suicidal ideation or behavior in 2020, as well as the approval of dextromethorphan-bupropion for the treatment of major depressive disorder in 2022.In order to help clinicians remain abreast of the latest treatment options for depression, PeerView recently held a Candid Conversations & Clinical Consults educational symposium, featuring a panel of psychiatric–mental health nursing faculty. These depression experts paired compelling, real-world case scenarios with practice-changing evidence to illustrate how to integrate novel and emerging treatments for depression into clinical practice, including strategies to identify patients who may benefit from these treatments, and how to use shared decision-making to craft individualized treatment plans. If you couldn't watch the live event, this on-demand version is available now!Co-Chair & ModeratorJosh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANPThe Hamilton Group Behavioral Health LLCLas Vegas, NevadaCo-Chair & PresenterRhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUERasmussen UniversityBloomington, Minnesota In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sage Therapeutics and Biogen.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJosh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alkermes and Point of Care Network, LLC (POCN).Speaker for Myriad Neuroscience and Point of Care Network, LLC (POCN).Co-Chair/PlannerRhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Point of Care Network (POCN).Speaker for Lippincott Clinical Pulse and Practical Updates in Primary Care.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Ridgeview Podcast: CME Series
Ankle Instability with Dr. Matt Weber

Ridgeview Podcast: CME Series

Play Episode Listen Later Oct 24, 2023 54:25


In this podcast, Dr. Matt Weber, a podiatrist with Ridgeview Specialty Clinics, brings his knowledge and experience around the causes of ankle instability, how common it is, and the different approaches for therapy and management. Enjoy the podcast. Objectives:Upon completion of this podcast, participants should be able to: Recognize ankle ligament instability from a patient's clinical history and exam. Diagnose ankle problems (pathology) assiciated with ankle instability, including acute injury vs. chronic conditions. Choose appropriate treatment protocols for an ankle instability condition. This activity has been planned and implemented in accordance with the accreditation criteria, standards and policies of the Minnesota Medical Association (MMA). Ridgeview is accredited by the Minnesota Medical Association (MMA) to provide continuing medical education for physicians.  CME credit is only offered to Ridgeview Providers & Allied Health staff for this podcast activity. After listening to the podcast, complete and submit the online evaluation form. Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at Education@ridgeviewmedical.org. Click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. Ridgeview's CME planning committee members and presenter(s) have disclosed they have no significant financial relationship with a pharmaceutical company and have disclosed that no conflict of interest exists with the presentation/educational event. Thank-you for listening to the podcast. SHOW NOTES:   *See the attachment for additional information.  PODCAST OVERVIEW Ankle Sprains - 25% go on to further sprains. - Graded 1-3 - Anatomy - Ottawa ankle rules - Physical therapy - Acute vs chronic Ankle Surgery - Brostrom Gold (pants over vest) - Attenuated Gracilis Repair - Following surgery - 3-4 weeks immobilized, then boot for 2-3 weeks, then physical therapy. - 4 months post injury - back to activity Thanks to Dr. Matt Weber for his expert knowledge and contribution to this podcast. Please check out the additional show notes for more information/resources.

Ridgeview Podcast: CME Series
Sports Medicine Potpourri with Dr. Bill Roberts

Ridgeview Podcast: CME Series

Play Episode Listen Later Sep 26, 2023 71:45


In this podcast, Dr. Bill Roberts - a family medicine physician and Professor Emeritus with the University of Minnesota. Dr. Roberts brings his vast expertise of sports medicine to discuss a potpourri of sports medicine topics. Enjoy the podcast. Objectives:Upon completion of this podcast, participants should be able to: Summarize the evolution of changes to sports medicine. Identify common sports related injuries and treatment modalities. Describe how supplements, substances and proformance enhancing drugs (PEDs) impact athletes and the environment of sports medicine. This activity has been planned and implemented in accordance with the accreditation criteria, standards and policies of the Minnesota Medical Association (MMA). Ridgeview is accredited by the Minnesota Medical Association (MMA) to provide continuing medical education for physicians.  CME credit is only offered to Ridgeview Providers & Allied Health staff for this podcast activity. After listening to the podcast, complete and submit the online evaluation form. Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at Education@ridgeviewmedical.org. Click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. Ridgeview's CME planning committee members and presenter(s) have disclosed they have no significant financial relationship with a pharmaceutical company and have disclosed that no conflict of interest exists with the presentation/educational event. Thank-you for listening to the podcast. SHOW NOTES:   *See the attachment for additional information.  Pre-participation Evaluation (sports qualifying exam) - Better screening questions and techniques - Mental health screening incorporation - Sudden Cardiac Death dilemma "Weekend Warrior" - Activity level and training for things (marathons, etc.) - when to check in with your provider. - More CAD in older marathoners who started training later in life - CAD, not long distance running, associated with Sudden Cardiac Arrest (SCA/SCD). Youth Athletes - Young children (pre-teen) should experience a wide variety of motor activities. - Life sports - throwing sports, running, biking, skiing "The Runner" - Start slow, build slow. - Overuse injuries Environmental - Heat and cold injuries "We've got an athlete down!" - SCA - sudden cardiac arrest - heat stroke - hypthermia - concussion/head injury - stroke or ICH (intracranial hemorrhage) - electrolytes (hyponatremia due to overhydration) Supplements, Substances and Performance Enhancement for Athletes - legal vs "illegal" - supplement use - "Eat well, sleep well, study well...." - peer and social pressure Pearls of Wisdom - pearls from Dr. Roberts Thanks to Dr. Bill Roberts for his expert knowledge and contribution to this podcast. Please check out the additional show notes for more information/resources.

Ridgeview Podcast: CME Series
Ridgeview Podcast Series - Season 6 Promotional Trailer

Ridgeview Podcast: CME Series

Play Episode Listen Later Aug 15, 2023 2:16


Promotional trailer to Ridgeview Podcast Series - Season 6

Write Medicine
The Vital Role of Integrity and Trust in CME

Write Medicine

Play Episode Listen Later Apr 19, 2023 34:12 Transcription Available


If you've been in the CME field for more than a hot minute, you'll know that Graham McMahon MD, MMSc is a medical educator, researcher, and practicing endocrinologist. He is the President and Chief Executive Officer of the Accreditation Council for Continuing Medical Education (ACCME®) and an Adjunct Professor of Medicine and Medical Education at Northwestern University.Today, we're talking about integrity and trust in CME. We dig into the factors that prompted the publication in 2020 of ACCME's report on standards for integrity and independence in CME, especially the emergence of potential threats to content credibility. Graham emphasizes the importance of nurturing innovation and retaining balance in education and points to the role of content validity as a core part of ACCME's standards and promise to the community of physician learners. We also talk about the centrality of trust in the process of teaching and learning,  how the concept of an educational home fosters trust among physician learners and the work to be done in the CME community to ensure safe learning spaces and create education that is diverse in focus, content, and faculty contribution. ResourcesAccreditation Council for Continuing Medical Education (ACCME®). Standards for Integrity and Independence in Accredited Continuing Education. 2020. McMahon GT. Changes to the Standards for Integrity and Independence in Continuing Medical Education. JAMA. 2021 Sklar DP, McMahon GT. Trust between teachers and learners. JAMA. 2019;321(22): 2157-2158Connect with GrahamAccreditation Council for Continuing Medical Education  ➡️ Join WriteCME Pro for ongoing professional development ⭐ Review the podcast

Ridgeview Podcast: CME Series
50 Years of Poison!...and a Toxicology Spy Tale with Dr. Jon Cole and Samantha Lee, PharmD

Ridgeview Podcast: CME Series

Play Episode Listen Later Mar 10, 2023 77:31


In this podcast, Dr. Jon Cole - an emergency medicine physician with Hennepin Healthcare and medical director with Minnesota Poison Control Center and Samantha Lee, PharmD - managing director with Minnesota Poison Control Center discuss the poison control system - past and present; along with a disscusion around toxicology - the big, the bad, and the ugly. Enjoy the podcast. Objectives:Upon completion of this podcast, participants should be able to: Describe the purpose of the Minnesota Poison Control Center, and how it works. Name the most common call types coming into MN Poison Control Center. Summarize the management of toxicological exposures for APAP, bupropion and calcium channel blockers. CME credit is only offered to Ridgeview Providers & Allied Health staff for this podcast activity. After listening to the podcast, complete and submit the online evaluation form.  Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at Education@ridgeviewmedical.org. Click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview Medical Center & Clinics.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. Ridgeview's CME planning committee members and presenter(s) have disclosed they have no significant financial relationship with a pharmaceutical company and have disclosed that no conflict of interest exists with the presentation/educational event. Thank-you for listening to the podcast. SHOW NOTES:  *See the attachment for additional information.  HISTORY of MN POISON CONTROL CENTER TOXICOLOGYCalcium Channel Blockers - Diltiazem, Verapamil, Amlodipine - Causes bad distributive shock - Pulmonary edema is an issue - Norepinephrine infusion is recommended in setting of shock with high dose insulin simultaneously - "Red, white and blue" therapy for refractory Ca++ blocker overdose - Activated charcoal - not for all patients, give if patient not at risk of aspiration for potentially lethal ingestions Bupropion - Chemical structure similar to amphetamine and bath salts - Sympathomimetic effects (tachycardia, agitation, seizures, ultimately cardiogenic shock) - Treatment with benzodiazepines - usually high dose - may need intubation - Norepinephrine for cardiogenic shock - ECMO may be needed Sodium Nitrite - Salt used to cure meats - Internet suicide phenomenon - Effect: Life threatening methemoglobinemia (chocolate colored blood, pallor, low O2 sats) - Very rapid onset of symptoms - Methylene Blue use N-acetylcysteine (NAC) for acetaminophen poisoning - Transitioning from 3 bag Prescott regimen to a 2 bag regimen - Rumack-Matthew nomogram is the same Article Resources:Cole JB, Lee SC, Prekker ME, Kunzler NM, Considine KA, Driver BE, Puskarich MA, Olives TD. Vasodilation in patients with calcium channel blocker poisoning treated with high-dose insulin: a comparison of amlodipine versus non-dihydropyridines. Clin Toxicol (Phila). 2022 Nov;60(11):1205-1213. doi: 10.1080/15563650.2022.2131565. Epub 2022 Oct 25. PMID: 36282196.   Cole JB, Olives TD, Ulici A, Litell JM, Bangh SA, Arens AM, Puskarich MA, Prekker ME. Extracorporeal Membrane Oxygenation for Poisonings Reported to U.S. Poison Centers from 2000 to 2018: An Analysis of the National Poison Data System. Crit Care Med. 2020 Aug;48(8):1111-1119. doi: 10.1097/CCM.0000000000004401. PMID: 32697480. Coralic Z, Kapur J, Olson KR, Chamberlain JM, Overbeek D, Silbergleit R. Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial. Ann Emerg Med. 2022 Sep;80(3):194-202. doi: 10.1016/j.annemergmed.2022.04.020. Epub 2022 Jun 17. PMID: 35718575. Kline JA, Tomaszewski CA, Schroeder JD, Raymond RM. Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharmacol Exp Ther. 1993 Nov;267(2):744-50. PMID: 8246150.   Thanks to Dr. Jon Cole and Samantha Lee, PharmD for their knowledge and contribution to this podcast. Please check out the additional show notes for more information/resources.

Nephrology Knowledge into Practice Podcast
FSGS: KDIGO 2021 guideline | With Dr Richard Glassock

Nephrology Knowledge into Practice Podcast

Play Episode Listen Later Dec 5, 2022 14:39


Description: In 2021, a work group of international experts published an update to the 2012 iteration of this guideline. To do so they reviewed the latest evidence through a systematic literature review, with the aim of providing a useful resource for clinicians caring for individuals with glomerular disease through actionable recommendations. In this episode we speak to Dr Richard Glassock, member of the work group, to hear his insights on the key takeaways from the guideline, and what has changed in this iteration. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. Reference: KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100(4S):S1–S276. Disclosures: Dr Richard Glassock declares the following: Stock Ownership - Reata Pharmaceuticals Speakers Bureau - Aurinia Advisory Board - Alexion, Bio-Cryst, Novartis, Otsuka, RenaSight, Travere, Vertex Consultant - Alexion, Arrowhead, Aurinia, Bio-Cryst, Calliditas, Chinook, Equillium, Horizon Pharma, Ionis, Midornid, Nephro-Sys, Omeros, River3Renal, Therini Bio, Travere, Vera Pharmaceuticals Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors. This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis. Discussion of Off-Label, Investigational or Experimental Drug Use: Corticosteroids are mentioned in the context of the treatment of FSGS. Funding: This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.

Nephrology Knowledge into Practice Podcast
IgAN: KDIGO 2021 guideline | With Prof. Jürgen Floege

Nephrology Knowledge into Practice Podcast

Play Episode Listen Later Nov 22, 2022 17:39


In 2021, a work group of international experts published an update to the 2012 iteration of this guideline. To do so they reviewed the latest evidence through a systematic literature review, with the aim of providing a useful resource for clinicians caring for individuals with glomerular disease through actionable recommendations. In this episode we speak to Professor Jürgen Floege, co-chair of the work group, to hear his insights on the key takeaways, and the clinical data that has emerged since the guideline update was made. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.  References available here Disclosures: Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.  This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.  Discussion of Off-Label, Investigational or Experimental Drug Use: Corticosteroids are mentioned in the context of the treatment of IgA nephropathy and reducing kidney function decline or failure. Funding: This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.

Diabetes Knowledge in Practice Podcast
Conference special: EASD 2022 Highlights | With Prof. Apostolos Tsapas

Diabetes Knowledge in Practice Podcast

Play Episode Listen Later Nov 14, 2022 18:25


This year's EASD was a hybrid event, with delegates able to join either in person in Stockholm, or online via the virtual platform. As usual, the congress featured a huge number of presented abstracts, symposia and other sessions. This year also saw the publication of the updated ADA-EASD consensus report on the management of hyperglycaemia in type 2 diabetes. Join us as we speak to Professor Apostolos Tsapas about his conference highlights, including: - 2022 ADA-EASD consensus report on the management of hyperglycaemia in type 2 diabetes - 44-year follow-up results from the UKPDS trial - Results from the DELIVER trial of dapagliflozin in heart failure - New data on once-weekly insulins By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com. Learning objectives and references available here Disclosures: Prof. Apostolos Tsapas declares the following financial relationships from the past 24 months: Consultant: Novo Nordisk Educational grant support: Eli Lilly Investigator: Boehringer Ingelheim Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. The content for this activity was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors. This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion. Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Ridgeview Podcast: CME Series
PICS: Post Intensive Care Syndrome with Dr. Tara McMichael & Clinical Nurse Specialist, Stacy Jepsen

Ridgeview Podcast: CME Series

Play Episode Listen Later Oct 28, 2022 65:37


For this podcast, we don't just have one but two guests. Returning to the show is Dr. Tara McMichael, an Internal Medicine Physician with Lakeview Clinic and Internist for Ridgeview, and Stacy Jepsen, a clinical nurse specialist with Ridgeview. During this podcast, Dr. McMichael and Stacy will be discussing Post Intensive Care Syndrome, also known as PICS. They will both bring unique perspectives from the initial critical illness and care in the ICU to the patient's outpatient visits and long term prognosis. Enjoy the podcast. Objectives:Upon completion of this podcast, participants should be able to: Define post intensive care syndrome (PICS) and post intensive care syndrome-family (PICS-F). Identify risk factors for devcelopment of PICS and PICS-F. Summarize prevention and treatment strategies for PICS and PICS-F Interpret the prevalence of PICS within the community. Utilize available resources to support patients/families with PICS symptoms. Describe how patients and their families can be supported who are struggling with PICS. CME credit is only offered to Ridgeview Providers & Allied Health Staff for this podcast activity. Complete and submit the online evaluation form, after viewing the activity.  Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at  Education@ridgeviewmedical.org. To receive continuing education credit for this activity - click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview Medical Center & Clinics.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. Ridgeview's CME planning committee members and presenter(s) have disclosed they have no significant financial relationship with a pharmaceutical company and have disclosed that no conflict of interest exists with the presentation/educational event. Thank-you for listening to the podcast. SHOW NOTES:  *See the attachment for additional information.  CLINICAL NURSE EDUCATOR- Advance practice RN who operates as an expert clinician, educator, researcher or consultant. - Masters or doctorate degree - Role had been around the US for over 60 years. POST INTENSIVE CARE SYNDROME (PICS)- New or worsening cognitive, psychological, physical limitation, post survival of critical illness and stay in ICU. - Post intensive care syndrome - family (PICS): family memvers who have mental limiations from the experience of having a loved on eiwth a critical illness. - First defined by Society of Critical Crea Medicine in 2010. - Remains difficult to diagnose for coding and reimbursement. ICD-10 code does not exsist. RISK FACTORS - critical illness with stay in ICU- Delirium- Sedataion during hostpital stay- Diagnosis of sepsis, ARDS, etc. DIAGNOSIS - Cognitive: short term memory loss, slow cognition, mental disorganization - Physical: changes in balance and gait - Psychological: anxiety, depression, insomnia, PTSD TESTING - no specific tests available for PICS          - MoCa           - Mini mental status           - PHQ9 (in setting of depression)           - GAD7 (in setting of anxiety) - two or more symptoms in any category - cognitive, physical and psychological 4-6 weeks post hspitalization. PREVALENCE - Of 5.8 ICU admissions, 4.8 million survive - Of the 4.8 million survivors, 50-80% will beet diagnostic criteria - COVID has brought PICS to forefront. PREVENTION- Prevention tips (multidisciplinary rounds, ABCDEF bundle, checklists for goals, support groups)- ABCDEF Bundle    A - Assess, precent and manage pain     B - Sedation reduction and vent weaning     C - Choice of analgesic and sedation      D - delirium prevention, recognition and treatment     E - Early mobility     F - Family BARRIERS - Communication, not true barrier, but requires effort PICS RESOURCES & TREATMENT - PICS clinics (pros & cons) - For primary care physician (it exists, dont; have to solve it one go; there are online resources available) - Addition PICS resources (listed in show notes). Thanks for listening.Please check out the additonal show notes for additional resources.

Nephrology Knowledge into Practice Podcast
IgAN: Current and future therapies | With Prof. Rosanna Coppo

Nephrology Knowledge into Practice Podcast

Play Episode Listen Later Oct 20, 2022 17:12


Current standard of care for IgA nephropathy (IgAN) involves optimized supportive care, antihypertensives, and dietary and lifestyle modifications. Despite these interventions, ~30% of patients progress to end stage renal disease. Recent approvals of delayed-release budesonide for IgAN and dapagliflozin for chronic kidney disease, and further investigational agents have the potential to alter the treatment landscape for IgAN. In this episode, Professor Rosanna Coppo offers her expert insight into the potential clinical implications of current and investigational therapies, both now and in the future. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References: References available here This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education. Disclosures: Prof. Rosanna Coppo has no disclosures to declare. Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors. This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis. Discussion of Off-Label, Investigational or Experimental Drug Use: Atrasentan, C5 inhibitor RNA therapies, eculizumab, empagliflozin, iptacopan, narsoplimab, ravulizumab, and sparsentan are mentioned in the context of the treatment of IgA nephropathy and reducing kidney function decline or failure. Sparsentan is also discussed in the context of the treatment of focal segmental glomerulosclerosis. Funding: This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.

Nephrology Knowledge into Practice Podcast
FSGS: Current and future therapies | With Dr. Kirk Campbell

Nephrology Knowledge into Practice Podcast

Play Episode Listen Later Oct 20, 2022 13:18


Historically, treatment options for focal segmental glomerulosclerosis (FSGS) have been limited to high-dose corticosteroids or calcineurin inhibitors in those ineligible or intolerant to steroids. However, an increase in clinical trial activity in the field of kidney disease may carry hope for novel therapeutic options for FSGS. This is illustrated by the recent approval of dapagliflozin for chronic kidney disease. In this episode, Dr. Kirk Campbell offers his expert opinion into the potential clinical implications of current and investigational therapies, both now and in the future. Learning objective After listening to this podcast series, learners will be able to recall the potential clinical implications of current and investigational therapies for FSGS. References available here Disclosures Dr. Kirk Campbell declares the following financial relationships from the past 24 months: Consultant - ANI, Calliditas, Chinook, Travere Research/grant support - Vertex Liberum IME staff, ACHL staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors. This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labelling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labelled for the use under discussion. Funding: This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.

Diabetes Knowledge in Practice Podcast
Publication special: Data from the SURPASS program | With Prof Carol Wysham

Diabetes Knowledge in Practice Podcast

Play Episode Listen Later Sep 27, 2022 13:35


The SURPASS program of phase 3 clinical trials led to the 2022 FDA approval and positive CHMP opinion of the first GIP/GLP-1 receptor agonist, tirzepatide. Join Prof Carol Wysham for an examination of the clinical data from these trials and their potential impact on type 2 diabetes management. By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. Learning objective After listening to this podcast series, learners will be able torecall the results of recent clinical trials for GIP/GLP-1 dual agonists References available here Disclosures Prof. Carol Wysham declares the following financial relationships from the past 24 months: Research Funding: Novo Nordisk; Eli Lilly Liberum IME staff, ACHL staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors. This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion. Funding: This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.

Diabetes Knowledge in Practice Podcast
Tailoring GLP-1 RA dosing regimens | With Dr Harpreet Bajaj

Diabetes Knowledge in Practice Podcast

Play Episode Listen Later Sep 12, 2022 14:05


Heterogeneity across available glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes means that agents should be prescribed based on patient characteristics and preferences. So how can we best make that decision? Join Dr Harpreet Bajaj for a discussion of tailoring GLP-1 RA regimens to patient characteristics, including considerations for dosing and treatment intensification. By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment. References available here Dr Harpreet Bajaj declares the following financial relationships from the past 24 months: Grants/Research Support: Eli Lilly, Novo Nordisk, Sanofi Liberum IME staff, ACHL staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors. This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion. Target Audience This educational activity is intended for an international audience of non-US and non-UK HCPs. Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Ridgeview Podcast: CME Series
Ridgeview Podcast Series - Season 5 Promotional Trailer

Ridgeview Podcast: CME Series

Play Episode Listen Later Aug 22, 2022 3:29


Promotional trailer to Ridgeview Podcast Series - Season 5.

Ridgeview Podcast: CME Series
The Agony of the Sweet: Diabetic Ketoacidosis (DKA) with Dr. Greg Geise

Ridgeview Podcast: CME Series

Play Episode Listen Later Apr 8, 2022 68:25


In this podcast,Dr. Greg Giese, an internal medicine physician with Ridgeview talks about diabetic ketoacidosis (DKA). More specifically Dr. Giese will discuss the pathophysiology, initial assessment findings and diagnosis of DKA, along with addressing the differences between diabetic ketoacidosis (DKA) and hypersmolar hyperglycemic state (HHS), and treatment options for DKA patients. Enjoy the podcast! Objectives:   Upon completion of this podcast, participants should be able to: Define diabetic ketoacidosis. State the differences between diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS). Summarize how to diagnose and treat diabetic ketoacidosis. CME credit is only offered to Ridgeview Providers & Allied Health Staff for this podcast activity. Complete and submit the online evaluation form, after viewing the activity.  Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at  rmccredentialing@ridgeviewmedical.org. To receive continuing education credit for this activity - click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview Medical Center & Clinics.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. Ridgeview's CME planning committee members and presenter(s) have disclosed they have no significant financial relationship with a pharmaceutical company and have disclosed that no conflict of interest exists with the presentation/educational event. Thank-you for listening to the podcast. SHOW NOTES: *See the attachment for additional show information.  DKA: Deficit of insulin- Typical scenario     - Insulin deficienty + counterregulatory hormones     - Catabolic state     - Gluconeogensis     - Glycogenolysis     - Elevated blood sugar causes concomitant osmotic       diuresis DKA: 3 Parts- Ketones (ketonemia) - Hyperglycemia (lack of insulin) - Acidosis (Anion gap Metabolic Acidosis) Presentation- Critically ill individual on set in 24-48 hours - Kussmaul respirations - Other causes (infections, UTI, pneumonia, skin    infections, MI, drugs,) - Altered mental status - HHS: Hyperosmolar hyperglycemic state Work-up- Basics CBC with differential; metabolic panel, serum ketones, blood gas, urine analysis, plasma osmolality - Evaluation: Elevated WBC;  elevated anion gap;  electrolyte abnormalities;  Chest x-ray Results- Potassium (hold insulin if K was 3.4 or below) - Hyponatremia - Bicarb - Anion gap - Normal to elevated calcium - BUN greater than creatinine ration - Elevated creatinine - Elevated WBC due to catecholamines and stress response - Hgb/platelets - Urine Treatment- Fluids - Potassium - Insulin Transition to baseline- Discontinue insulin when anion gap metabolic acidosis closed and able to take oral nutrition- Bridge, start subcutaneous long acting insulin, stop insulin drip 1-2 hours later. Thanks for listening.

Ridgeview Podcast: CME Series
Into the Weeds (Part 1): Pre and Post Acute Kidney Injury with Dr. Kim Thielen

Ridgeview Podcast: CME Series

Play Episode Listen Later Mar 11, 2022 45:52


In this podcast, we are joined by Dr. Kim Thielen, a nephrologist/kidney specialist with Minnesota Kidney Specialists. This episode is part one of a two part series dealing with acute kidney injuries. During this episode Dr. Thielen will discuss pre and post acute kidney injury etiologies. Included with the podcast is additional shownotes that Dr. Thielen references throughout the podcast.  Also check out the next podcast/episode on intrinsic kidney injuries. Enjoy the podcast! Objectives:   Upon completion of this podcast, participants should be able to: Describe how to work up a patient who presents with kidney injury. State the 3 types of kidney injury etiologies. Identify various causes of kidney injury. Choose treatment options for the specific types of kidney injury. CME credit is only offered to Ridgeview Providers & Allied Health Staff for this podcast activity. Complete and submit the online evaluation form, after viewing the activity.  Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at  rmccredentialing@ridgeviewmedical.org. To receive continuing education credit for this activity - click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview Medical Center & Clinics.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. Ridgeview's CME planning committee members and presenter(s) have disclosed they have no significant financial relationship with a pharmaceutical company and have disclosed that no conflict of interest exists with the presentation/educational event. Thank-you for listening to the podcast. SHOW NOTES: *See the attachment for additional show information.   Acute Kidney Injury- Abrupt decrease in kidney function - Suspected with oliguria, elevated creatinine, proteinuria, and hematuria Oliguria - Less than 500mls of urine in 24 hour period. PreRenal- Anything that decreases circulating volume or disruption of blood flow to the kidney, causing ischemic kidney - Causes:     - Total body salt and water depletion     - Dehydration     - Hemorrhage     - Decompensated right or left ventricular failure     - Renal arterial stenosis or renal vasospasm Signs and Symptoms - Orthostatic, hypotensive, tachycardiac - Most sensitive indicator of ischemic kidney: Urinary sodium concentration Urinary Sodium Concentration- Distinguishes between prerenal and instrinsic causes - Urine sodium less than 20 in oliguria is indicator of ischemic kidney Fractional Excretion of Sodium- Fractional excretion of less than 1% is indicative of ischemic kidney or a prerenal state - Fractional excretion of 2% is indicative of tubulules not working or ATN Fractional Excretion of Urea - For patients on diuretics - Urea not affected by water concentrating effect of kidney - Prerenal state: fractional excretion of urea less than 35 - Intrinsic: fractional excretion of urea greater than 35 Classic Presentation of Prerenal - BUN to Creatinine Ratio greater than 20.1 signifies dehydration       - Variables: GI bleed can increase BUN - Elevated bicarb Post Renal Etiologies - Anything that interfers with the drainage of the urine from the renal pelvis out to the urethra. - Causes:       - Intraluminal obstruction: stones or tumors       - Dysfunctional bladder: spinal injury, diabetes              - Dysfunction with bladder drainage       - Extrinsic compression on ureter                - Ruptured AAA: edema                - Retroperitoneal fibrosis                - Prostate                - Urethral strictures Post Renal Presentation - Can present with pain or not - Decreased urine output or outflow - Hypertensive - Volume overload Treatment - Foley distal obstructions of urethra - Imaging: ultrasound        - Horizontal view:               - Normal: (bright white) collecting system is collapsed due to normal drainage of pelvis               - Post renal obstruction                       - Dilated (dark pools) collecting system - Chronic obstruction        - Functional dilatation        - Further testing: functional lasix radiograph        - Kidney transplant: functional dilated picture               - Changed physiology of the ureter, and can get flow both ways and thus chronic dilation Thanks for listening.

Ridgeview Podcast: CME Series
The Void: Urinary Incontinence with Dr. Lioudmila Sitnikova

Ridgeview Podcast: CME Series

Play Episode Listen Later Feb 25, 2022 73:32


In this podcast, Dr. Lioudmila Sitnikova, a urologist with Minnesota Urology, discusses micturition, pathology of incontinence including stress, urge and neurological, as well as various treatments available. Enjoy the podcast! Objectives:   Upon completion of this podcast, participants should be able to: Describe the normal function of the bladder. List the different types of incontienence. Describe how female urinary incontinence is diagnosed. Identify treatment options for each type of urinary incontinence. CME credit is only offered to Ridgeview Providers & Allied Health Staff for this podcast activity. Complete and submit the online evaluation form, after viewing the activity.  Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at  rmccredentialing@ridgeviewmedical.org. To receive continuing education credit for this activity - click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview Medical Center & Clinics.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. Ridgeview's CME planning committee members and presenter(s) have disclosed they have no significant financial relationship with a pharmaceutical company and have disclosed that no conflict of interest exists with the presentation/educational event. Thank-you for listening to the podcast. SHOW NOTES: *See the atachment for the full chapter summaries.   Phases of Micturition- Storage - Evacuation Risk Factors - BMI, smoking, caffiene, spicy food, heavy lifting, child-bearing, diabetes, pelvic surgeries. Hormone Replacement Therapy (HRT)- Oral estrogen/progesterone vs placebo Prevalence - 1 out of 4 women over age 80 suffer incontinence. Types & identification- Stress incontinence - Urge incontinence - Overflow incontinece - Bladder outlet obstruction Evaluation for incontinence- Questionnaires - Voiding diaries - Assess quality of life - Physical assessment and pelvic exam Treatment - Stress incontinence: physical therapy, surgical, bulking agents, Burch procedure - Urge incontinence: biofeedback, antimuscarinics and Beta 3 agonists, Botox, nerve stimulator - Hypotonic bladder (non-obstructive urinary retention): nerve stimulator *For links to reference materials please see the full show notes.

Ridgeview Podcast: CME Series
2021-22 Stroke Updates with Dr. Ron Tarrel

Ridgeview Podcast: CME Series

Play Episode Listen Later Jan 28, 2022 71:32


In this podcast, Dr. Ron Tarrel, a Stroke Neurologist with Allina Health, discusses everything stroke. Dr. Tarrel walks through recognition, evaluation, and management of stroke. He also discusses current guidelines, as well as the future of stroke medicine. Enjoy the podcast! Objectives:   Upon completion of this podcast, participants should be able to: Identify and describe warning signs of stroke and its initial presentation. Assess when initial urgent/emergent evaluation, imaging, coordination of care and decision making needs to occur in regards to stroke. Discuss treatment options and indications in regards to stroke care. CME credit is only offered to Ridgeview Providers & Allied Health Staff for this podcast activity. Complete and submit the online evaluation form, after viewing the activity.  Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at  rmccredentialing@ridgeviewmedical.org. To receive continuing education credit for this activity - click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview Medical Center & Clinics.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. Ridgeview's CME planning committee members and presenter(s) have disclosed they have no significant financial relationship with a pharmaceutical company and have disclosed that no conflict of interest exists with the presentation/educational event. Thank-you for listening to the podcast. ADDENDUM TO SHOW NOTES:Please note the Dr. Tarrel refers to TPA as a blood thinner at one point throughout the podcast. He would like the listerner to know that this medication (TPA) is a clot dissolving medication and not a blood thinner. Dr. Tarrel does not wish to confuse the listner on the nomenclature of TPA vs blood thinners (i.e. anticoagulants). SHOW NOTES: FAST The American Heart Association (AHA) put forth an initative for the lay person to recognize signs and symptoms of stroke and that was the FAST assessment which is (Facial asymmetry or weakness, Arm weakness, Speech difficulties, and Time), but now it has moved to the BE-FAST screening test. the BE portion of the FAST exam is assessment of Balance and Eyes to determine if there are posterior circulation findings. https://www.ahajournals.org/doi/epub/10.1161/STROKEAHA.116.015169 HINTS ExamThe HINTS exam is a bit more specific and sensitve, looking for posterior circulation strokes in the correct patient population. Briefly, HINTS is a Head Impulse test direction-changing Nystagmus in eccentric gaze, or skew deviation. https://www.ahajournals.org/doi/epub/10.1161/STROKEAHA.109.551234 Common DeficitsThe majority of strokes are going to occur in the anterior circulation which would be the carotid distribution, then into MCA (M1, M2, M3, M4, M5). Most of the deficits are going to be unilateral weakness, sensory or cognitive symptoms - example: aphasia/ neglect (cortical symptoms). Whereas, posterior circulation (vertebrobasilar) may have more devastating qualities. Symptoms for posterior stroke can include dizziness, nausea and vomiting, nystagmus, coordination, ataxia. However, see the article linked below where posterior cirulation vs anterior crculation infarcts can sometimes be difficult to determine on a clinical exam alone. Therefore, neuroimaging is recommended to accurately determine stroke distribution. https://www.ahajournals.org/doi/epub/10.1161/STROKEAHA.112.652420 This study indicates that the symptoms/signs considered typical of posterior circulation infarcts occur far less often than was expected. Inaccurate localization would occur commonly if clinicians relied on the clinical neurological deficits alone to differentiate posterior circulation infarcts from anterior circulation infarcts. Neuroimaging is vital to ensure acurate localization of cerebral infarction. Hemorrhagic vs Ischemic StrokeWhich one is it? According to Dr. Tarrel, intracranial hemorrhage appears to exhibit more headache symptoms, such as this is the "worst headache of my life" , whereas ischemic stroke appears to be more painless, usually. Blood pressure and loss of consciousness can closely mimic hemorrhagic vs ischemic. Telestroke GuidelinesTelestroke guidelines are generally insitution specific. Refer to the linked article below, on the current guidelines in telestroke medicine. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802246/pdf/tmj.2017.0006.pdf BP / 1st Line AgentFor hemorrhagic strokes, the neurosurgeons and neurologist like the systolic blood pressure to be in the 140-160 range. BP is usually controlled with Nicardipine as a 1st line agent. https://www.ahajournals.org/doi/epub/10.1161/STROKEAHA.117.020058 Last Known Well (LKW)Last Known Well (LKW) is extremely important especially since we know that we are working against the closk for the use of lytic therapy (currently 4.5 hour window).https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630074/pdf/nihms699406.pdf https://www.ahajournals.org/doi/epub/10.1161/CIRCULATIONAHA.116.023336 Imaging Imaging modalities for stroke workup can often include an initial non-contrast CT of the head to rule out ICH, but hen what happens? Generally, it is recommended to work in concert with the stroke neurologist to then determine the next line of imaging studies. If it is determined the patient looks to have a high NIHSS and concerns for LVOT (Large Vessel Occulusion) a CTA of the head and neck can be considered. Perfusion studies and advanced MR imaging should be discussed with consulting neurologists. Clinicians should also remember to follow their specific institutional guidelines for imaging studies if the stroke neurologist is unavailable or there is a delay in consultation. LKW along with CTA and CT perfusion of the head in ischemic stroke patients can sometimes give us a picture of the infarct core with surrounding penumbra (ratio). If circumstances are faborable, it may allow the pursuit of a thrombectomy. The current guidelines are for thrombectomy within 6 hours, but consideration upwards of 24 and beyond in the right patient population. Please see the DAWN and DIFFUSE 3 trials. https://www.ahajournals.org/doi/epub/10.1161/STROKEAHA.119.027974 ThrombectomyGenerally the neurointerventionalist does not pursue thrombectomy beyond the MCA (M2 region), sometimes depending on anatomy. ASPECT ScoreThe ASPECT Score (Alberta Stroke Program Early CT Score) determines the volume of subcortical and cortical infarct involvement via perfusion study. Generally the score provided is 1-10. Anything less than a 6 portends a poor outcome. More early changes seen on CT suggest poorer outcomes from stroke. Patients with scores >8 have a better chance for an independent outcome. https://www.ahajournals.org/doi/epub/10.1161/STROKEAHA.117.016745 IV TPAIV TPA with thrombectomy is safe. https://www.ahajournals.org/doi/epub/10.1161/STROKEAHA.109.568451 TNK appears to have the same efficacy as TPA. Single dose IV push over 5 minute infusion. Easier and faster delivery of TNK. https://www.ahajournals.org/doi/epub/10.1161/STROKEAHA.119.025080 Institutions may have different absolute and relative contraindications to TPA. Practice should be guided by institutional protocol and consultation with neurology. https://www.ahajournals.org/doi/epub/10.1161/STR.0000000000000086 Secondary PreventionSecondary prevention of stroke with the aid of DAPT (Dual Antiplatelet Therapy) - usually Plavix and Aspirin. Patients with cerebra ischemia are at high risk for early recurrent stroke, and use of DAPT for secondary prevention is reflected in current guidelines. Good BP and lipid management is paramount for 2nd stroke prevention. https://www.ahajournals.org/doi/epub/10.1161/STROKEAHA.119.028400 Scoring SystemsHAS-BLED score for major bleeding risk. CHA2DS2-VASc Score for artrial fibrillation stroke risk. Anti-thrombotic Therapy & Elderly PatientsChoosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls.https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/484991 Fall risk and anticoagulatoin for atrial fibrillation in the elderly: A delicate balance. https://www.ccjm.org/content/ccjom/84/1/35.full.pdf  

Write Medicine
Adult Learning in a Virtual World: Instructional Design and E-Learning

Write Medicine

Play Episode Listen Later Nov 1, 2021 39:31 Transcription Available


One of the consequences of the COVID-19 pandemic has been the massive shift from live meetings and education to virtual formats and the longer term implications of this shift is an ongoing conversation in the continuing healthcare education world. The 2020 ACCME Annual Report noted that online activities engaged most learners compared with live courses and regularly scheduled series, the dominant activity types in preceding years. The shift to online education is itself not new in the US although its expansion has been patchy and there are several factors that pose barriers to the development and implementation of online learning, such as time constraints, poor technical skills, inadequate infrastructure, absence of institutional strategies and support and negative attitudes. As a result of these  barriers, as well as the impact of the evolving science of learning, the demand for instructional designers in continuing healthcare education is increasing. One study predicts that by 2025, there will be a 28% in ID jobs in education.But what do instructional designers do and what is their role in continuing healthcare education? My guest today Jessica Martello answers those questions. As VP of of content and editorial at EVERFI, a digital education company, Jessica brings deep expertise to the potential of instruction design in adult learning. Join us to hear more about:The key components of an effective digital learning platformKey factors to optimize digital learning platformsHow to assess learning outcomes in digital educationChallenges that adults experience in relation to online learningResourcesEVERFIOn Being with Krista Tippett: Ariel Berger—Be a BlessingInstructional Design Resources from ACCMEAccreditation Council for Continuing Medical Education (ACCME). ACCME Data Report. Rising to the Challenge in Accredited Continuing Education—2020. Love LM, Anderson MC, Haggar FL. Strategically integrating instructional designers in medical education. Academic Medicine. 2019;94:146.Snell L, Son D, Onishi H. Instructional Design. Applying Theory to Practice. In Swanwick T, Forrest K, O'Brien BC (eds) Understanding Medical Education: Evidence, Theory, and Practice. Third Edition. 2018. London: Wiley.Connect with JessieConnect with AlexPodcast TeamHost: Alexandra Howson PhDSound Engineer: Suzen MarieShownotes: Linzy Carothers